Literature DB >> 29521097

Characterization of an A-Site Selective Protein Disulfide Isomerase A1 Inhibitor.

Kyle S Cole1, Julia M D Grandjean2, Kenny Chen3, Collin H Witt1, Johanna O'Day1, Matthew D Shoulders3, R Luke Wiseman2, Eranthie Weerapana1.   

Abstract

Protein disulfide isomerase A1 (PDIA1) is an endoplasmic reticulum (ER)-localized thiol-disulfide oxidoreductase that is an important folding catalyst for secretory pathway proteins. PDIA1 contains two active-site domains (a and a'), each containing a Cys-Gly-His-Cys (CGHC) active-site motif. The two active-site domains share 37% sequence identity and function independently to perform disulfide-bond reduction, oxidation, and isomerization. Numerous inhibitors for PDIA1 have been reported, yet the selectivity of these inhibitors toward the a and a' sites is poorly characterized. Here, we identify a potent and selective PDIA1 inhibitor, KSC-34, with 30-fold selectivity for the a site over the a' site. KSC-34 displays time-dependent inhibition of PDIA1 reductase activity in vitro with a kinact/ KI of 9.66 × 103 M-1 s-1 and is selective for PDIA1 over other members of the PDI family, and other cellular cysteine-containing proteins. We provide the first cellular characterization of an a-site selective PDIA1 inhibitor and demonstrate that KSC-34 has minimal sustained effects on the cellular unfolded protein response, indicating that a-site inhibition does not induce global protein folding-associated ER stress. KSC-34 treatment significantly decreases the rate of secretion of a destabilized, amyloidogenic antibody light chain, thereby minimizing pathogenic amyloidogenic extracellular proteins that rely on high PDIA1 activity for proper folding and secretion. Given the poor understanding of the contribution of each PDIA1 active site to the (patho)physiological functions of PDIA1, site selective inhibitors like KSC-34 provide useful tools for delineating the pathological role and therapeutic potential of PDIA1.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29521097      PMCID: PMC5884060          DOI: 10.1021/acs.biochem.8b00178

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  43 in total

1.  Enhanced protein levels of protein thiol/disulphide oxidoreductases in placentae from pre-eclamptic subjects.

Authors:  E Shibata; K Ejima; H Nanri; N Toki; C Koyama; M Ikeda; M Kashimura
Journal:  Placenta       Date:  2001-07       Impact factor: 3.481

2.  Activation of the unfolded protein response in Parkinson's disease.

Authors:  J J M Hoozemans; E S van Haastert; P Eikelenboom; R A I de Vos; J M Rozemuller; W Scheper
Journal:  Biochem Biophys Res Commun       Date:  2007-01-17       Impact factor: 3.575

3.  The b' domain provides the principal peptide-binding site of protein disulfide isomerase but all domains contribute to binding of misfolded proteins.

Authors:  P Klappa; L W Ruddock; N J Darby; R B Freedman
Journal:  EMBO J       Date:  1998-02-16       Impact factor: 11.598

4.  In vivo cross-linking of protein disulfide isomerase to immunoglobulins.

Authors:  R A Roth; S B Pierce
Journal:  Biochemistry       Date:  1987-07-14       Impact factor: 3.162

5.  Effect of increased expression of protein disulfide isomerase and heavy chain binding protein on antibody secretion in a recombinant CHO cell line.

Authors:  Nicole Borth; Diethard Mattanovich; Renate Kunert; Hermann Katinger
Journal:  Biotechnol Prog       Date:  2005 Jan-Feb

6.  Small molecule probe suitable for in situ profiling and inhibition of protein disulfide isomerase.

Authors:  Jingyan Ge; Chong-Jing Zhang; Lin Li; Li Min Chong; Xiaoyuan Wu; Piliang Hao; Siu Kwan Sze; Shao Q Yao
Journal:  ACS Chem Biol       Date:  2013-09-26       Impact factor: 5.100

7.  Influence of protein disulfide isomerase (PDI) on antibody folding in vitro.

Authors:  H Lilie; S McLaughlin; R Freedman; J Buchner
Journal:  J Biol Chem       Date:  1994-05-13       Impact factor: 5.157

Review 8.  Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.

Authors:  Morie A Gertz
Journal:  Am J Hematol       Date:  2016-09       Impact factor: 10.047

9.  Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment.

Authors:  Shili Xu; Alexey N Butkevich; Roppei Yamada; Yu Zhou; Bikash Debnath; Roger Duncan; Ebrahim Zandi; Nicos A Petasis; Nouri Neamati
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-17       Impact factor: 11.205

Review 10.  The mammalian unfolded protein response.

Authors:  Martin Schröder; Randal J Kaufman
Journal:  Annu Rev Biochem       Date:  2005       Impact factor: 23.643

View more
  16 in total

1.  Triazine Probes Target Ascorbate Peroxidases in Plants.

Authors:  Kyoko Morimoto; Kyle S Cole; Jiorgos Kourelis; Collin H Witt; Daniel Brown; Daniel Krahn; Monika Stegmann; Farnusch Kaschani; Markus Kaiser; Jonathan Burton; Shabaz Mohammed; Kazuko Yamaguchi-Shinozaki; Eranthie Weerapana; Renier A L van der Hoorn
Journal:  Plant Physiol       Date:  2019-05-28       Impact factor: 8.340

2.  Quantitative Interactome Proteomics Reveals a Molecular Basis for ATF6-Dependent Regulation of a Destabilized Amyloidogenic Protein.

Authors:  Lars Plate; Bibiana Rius; Bianca Nguyen; Joseph C Genereux; Jeffery W Kelly; R Luke Wiseman
Journal:  Cell Chem Biol       Date:  2019-05-16       Impact factor: 8.116

Review 3.  Targeting defective proteostasis in the collagenopathies.

Authors:  Madeline Y Wong; Matthew D Shoulders
Journal:  Curr Opin Chem Biol       Date:  2019-04-24       Impact factor: 8.822

4.  Pharmacologic targeting of plasma cell endoplasmic reticulum proteostasis to reduce amyloidogenic light chain secretion.

Authors:  Bibiana Rius; Jaleh S Mesgarzadeh; Isabelle C Romine; Ryan J Paxman; Jeffery W Kelly; R Luke Wiseman
Journal:  Blood Adv       Date:  2021-02-23

5.  Identifying Interaction Partners of Yeast Protein Disulfide Isomerases Using a Small Thiol-Reactive Cross-Linker: Implications for Secretory Pathway Proteostasis.

Authors:  Benjamin J Freije; Wilson M Freije; To Uyen Do; Grace E Adkins; Alexander Bruch; Jennifer E Hurtig; Kevin A Morano; Raffael Schaffrath; James D West
Journal:  Chem Res Toxicol       Date:  2022-01-27       Impact factor: 3.739

6.  A Role for Basigin in Toxoplasma gondii Infection.

Authors:  Azadeh Nasuhidehnavi; Yanlin Zhao; Ankita Punetha; Andrew Hemphill; Hong Li; Tyler J Bechtel; Theresa Rager; Bingcong Xiong; Vasileios I Petrou; Marc-Jan Gubbels; Eranthie Weerapana; George S Yap
Journal:  Infect Immun       Date:  2022-08-01       Impact factor: 3.609

7.  Tuning isoform selectivity and bortezomib sensitivity with a new class of alkenyl indene PDI inhibitor.

Authors:  Reeder M Robinson; Leticia Reyes; Ravyn M Duncan; Haiyan Bian; Eric D Strobel; Sarah L Hyman; Allen B Reitz; Nathan G Dolloff
Journal:  Eur J Med Chem       Date:  2019-11-21       Impact factor: 6.514

Review 8.  Role of the ERO1-PDI interaction in oxidative protein folding and disease.

Authors:  Andrea G Shergalis; Shuai Hu; Armand Bankhead; Nouri Neamati
Journal:  Pharmacol Ther       Date:  2020-03-20       Impact factor: 12.310

9.  PDIA1/P4HB is required for efficient proinsulin maturation and ß cell health in response to diet induced obesity.

Authors:  Insook Jang; Anita Pottekat; Juthakorn Poothong; Jing Yong; Jacqueline Lagunas-Acosta; Adriana Charbono; Zhouji Chen; Donalyn L Scheuner; Ming Liu; Pamela Itkin-Ansari; Peter Arvan; Randal J Kaufman
Journal:  Elife       Date:  2019-06-11       Impact factor: 8.140

10.  Characterization of Aminobenzylphenols as Protein Disulfide Isomerase Inhibitors in Glioblastoma Cell Lines.

Authors:  Andrea Shergalis; Ding Xue; Fatma Z Gharbia; Hannah Driks; Binita Shrestha; Amina Tanweer; Kirin Cromer; Mats Ljungman; Nouri Neamati
Journal:  J Med Chem       Date:  2020-09-11       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.